A report released today by Jefferies about AC Immune (NASDAQ:ACIU) ups the target price to $25.00
- Updated: October 18, 2016
Reporting a potential upside of 0.73%, Jefferies upped the price target of AC Immune (NASDAQ:ACIU) to $25.00
Having a price of $14.43, AC Immune (NASDAQ:ACIU) traded 5.27% higher on the day. With the last stock price down -6.04% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. ACIU has recorded a 50-day average of $16.17 and a two hundred day average of $16.17. Trade Volume was down over the average, with 252,119 shares of ACIU changing hands under the typical 521,300
Recent Performance Chart
AC Immune has PE ratio of 32.81 with a one year low of $13.01 and a one year high of $19.97 and has a market capitalization of $0.
General Company Details For AC Immune (NASDAQ:ACIU)
AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer's and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson's, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.